drugset
drugset / Trial / NCT05760937

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

NCT05760937 ↗

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability and drug levels of single, oral doses of BMS-986447 in healthy participants.

Timeline

Start
2023-03-10
Primary completion
2023-11-27
Completion
2023-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986447 Unknown — Oral

Indications

No indication recorded.